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Abstract
Background: The purpose of the work reported here is to test reliable molecular profiles using routinely processed
formalin-fixed paraffin-embedded (FFPE) tissues from participants of the clinical trial BIG 1-98 with a median follow-
up of 60 months.
Methods: RNA from fresh frozen (FF) and FFPE tumor samples of 82 patients were used for quality control, and
independent FFPE tissues of 342 postmenopausal participants of BIG 1-98 with ER-positive cancer were analyzed by
measuring prospectively selected genes and computing scores representing the functions of the estrogen receptor
(eight genes, ER_8), the progesterone receptor (five genes, PGR_5), Her2 (two genes, HER2_2), and proliferation
(ten genes, PRO_10) by quantitative reverse transcription PCR (qRT-PCR) on TaqMan Low Density Arrays. Molecular
scores were computed for each category and ER_8, PGR_5, HER2_2, and PRO_10 scores were combined into a
RISK_25 score.
Results: Pearson correlation coefficients between FF- and FFPE-derived scores were at least 0.94 and high
concordance was observed between molecular scores and immunohistochemical data. The HER2_2, PGR_5,
PRO_10 and RISK_25 scores were significant predictors of disease free-survival (DFS) in univariate Cox proportional
hazard regression. PRO_10 and RISK_25 scores predicted DFS in patients with histological grade II breast cancer
and in lymph node positive disease. The PRO_10 and PGR_5 scores were independent predictors of DFS in
multivariate Cox regression models incorporating clinical risk indicators; PRO_10 outperformed Ki-67 labeling index
in multivariate Cox proportional hazard analyses.
Conclusions: Scores representing the endocrine responsiveness and proliferation status of breast cancers were
developed from gene expression analyses based on RNA derived from FFPE tissues. The validation of the molecular
scores with tumor samples of participants of the BIG 1-98 trial demonstrates that such scores can serve as
independent prognostic factors to estimate disease free survival (DFS) in postmenopausal patients with estrogen
receptor positive breast cancer.
Trial Registration: Current Controlled Trials: NCT00004205
Background
Clinical and histopathological factors such as lymph
node status, tumor size, histological grade, age, and
expression of estrogen receptor (ER) and Her2 have tra-
ditionally guided treatment decisions of patients with
operable breast cancer [1,2]. Various prognostic models
are based on these factors, for example the Nottingham
Prognostic Index (NPI) [3,4], Adjuvant!Online [5,6] and
others [7]. Despite providing excellent estimates of the
average risk of recurrence, there remains substantial var-
iation in outcome which may be explained by molecular
differences among these tumors [8,9].
DNA-chip based expression analyses have confirmed
the heterogeneity of breast cancer and allowed the
development of clinically relevant gene “signatures” or
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“profiles” [10-20]. Such profiles are being implemented
widely in routine patient care even though many signa-
tures were developed and validated on heterogeneous
patient cohorts with respect to stage of disease and ther-
apy. The utility of gene signatures as part of the decision
making process is being validated in ongoing studies
(TAILORx [21] and MINDACT [22]). Most profiling
studies are based on fresh-frozen (FF) or RNAlater con-
served tissue. Such material must be collected and pro-
cessed separately after surgery, complicating the
implementation of molecular analyses into the clinical
workflow. Procedures based on formalin-fixed, paraffin-
embedded (FFPE) material simplify the acquisition of
tumor material and can easily be established as part of
the routine pathological procedures. In addition, FFPE
tissues collected in the framework of clinical trials could
be a valuable resource for future research.
We prospectively selected genes from publicly avail-
able microarray data and developed molecular scores
representing the ER, progesterone receptor (PgR), Her2
and proliferation (PRO) status, and the overall risk of
recurrence (RISK). The reproducibility and robustness
of the molecular scores was validated by comparing
expression data with RNA from FF and FFPE material
of 82 tumors. Molecular scores were determined from
342 ER positive tumor samples of the BIG 1-98 clinical
trial. Multivariate Cox proportional hazard models
revealed that molecular scores are independent prognos-
tic factors to estimate disease free survival (DFS).
Methods
To assess the quality of expression profiling from FFPE
material, matched FF and FFPE samples from 82
human breast cancers were used. Histopathological
information was irreversibly anonymized according to
Swiss law. Independent FFPE blocks and corresponding
clinical data of 437 Swiss participants of the trial BIG 1-
98 were provided by the International Breast Cancer
Study Group. The ethics committees and required
health authorities of each participating institution
approved the study protocol, and all patients gave writ-
ten informed consent (ClinicalTrials.gov number,
NCT00004205) [23]. Retrospective tissue collection was
carried out in accordance with institutional guidelines
and national laws. The patient and tumor characteristics
of these patients were similar to the entire BIG 1-98
population (Table 1). BIG 1-98 is a randomized con-
trolled clinical trial of adjuvant hormonal therapy for
postmenopausal patients with endocrine-responsive
breast cancer comparing 4 arms: 5 years of tamoxifen, 5
years of letrozole, two years of tamoxifen followed by 3
years of letrozole, or vice versa [24-26]. All the patients
from the BIG 1-98 were treated by mastectomy or
breast conserving surgery [24-26]. The available paraffin
blocks contained material derived from representative
tumor regions.
Tissue samples and data processing
The RNA was isolated from 4 sections (25 μm) of FF
material and from 10 paraffin sections (10 μm thick) as
described previously [27]. After demodification, the
RNA was bound to silica-based columns, DNase I
digested and eluted with water. The protocols and
reagents for RNA isolation from FF and FFPE tissues
were recently incorporated in commercial protocols
(RNAready and FFPE RNAready, AmpTec, Hamburg,
Germany). RNA qualities were assessed on an Agilent
2100 Bioanalyzer (Agilent Technologies, Inc., Santa
Clara, CA, USA). RNA prepared from FF material had a
RIN>6 (RNA integrity number), the RIN of RNA from
FFPE was 2-3. The percentage of tumor cells in each
FFPE block was evaluated on stained tissue sections.
From 437 available FFPE samples 43 samples (9.8%)
with less than ~30% tumor cells, 10 ER-negative tumor
samples and 7 samples (1.6%) with less than 1.5 μg total
RNA recovery were excluded from further analysis.
Approximately 30% of the sections contained 30-50%
tumor cells, and about 60% contained 50-100% tumor
cells. Each of the remaining RNAs was tested by quanti-
tative reverse transcription PCR (qRT-PCR) with 3 con-
trol genes (GUSB, RPLP0 and UBB). The mean of the
three raw Cts (cycle thresholds) was determined. In 35
samples (8%) the mean Ct was >31, indicating poor
quality of the RNA. These RNAs were excluded from
further analyses. For the remaining 342 RNAs (78.3%),
the expression of 34 genes (see Table 1) was measured
by qRT-PCR on TaqMan Low Density Arrays (TLDAs)
(Applied Biosystems, Foster City, CA, USA) using a one
step protocol (Invitrogen, Basel, Switzerland) on an
Applied Biosystems 7900HT instrument. Technical
replicates were performed for several intact and several
partially degraded RNAs from FF and FFPE material,
respectively. They revealed Pearson correlation coeffi-
cients higher than 0.95 for all 34 assays.
Genes with high correlation to the expression of ER,
PgR, Her2 and proliferation related genes were prospec-
tively selected from publicly available microarray data
[28]. A complete list of microarray data sets used in the
meta-analysis is available at “.http://breast-cancer-
research.com/content/10/4/R65/table/T1[28] (Additional
File 1, Table S1). The scores were defined by giving
equal weight to each gene in the four groups (prolifera-
tion, estrogen response, progesterone response, Her2
response). Thus, a training set was not used as the
scores were based on in silico gene selection.
Raw Ct values were normalized against the mean
expression of GUSB, RPLP0 and UBB. Scores for ER
(ER_8), PgR (PGR_5), Her2 (HER2_2) and proliferation
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Table 1 Gene Identifications, Categories and Score affiliations
Gene Category Accession Nr. Description AS Score
GUSB Control NM_000181.1 glucuronidase, beta 81 control
RPLP0 Control NM_053275.3
NM_001002.3
ribosomal protein, large, P0 105 control
UBB Control NM_018955.2 ubiquitin B 120 control
AR ER NM_001011645.1
NM_000044.2
androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and
bulbar muscular atrophy; Kennedy disease)
72 ER_8
ERBB4 ER NM_001042599.1
NM_005235.2
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 77 ER_8
ESR1 ER NM_000125.2 estrogen receptor 1 62 ER_8
ER_4
FOXA1 ER NM_004496.2 forkhead box A1 74 ER_8
GATA3 ER NM_001002295.1
NM_002051.2
GATA binding protein 3 80 ER_8
MAPT ER NM_016834.2
NM_016835.2
NM_016841.2
NM_005910.3
microtubule-associated protein tau 60 ER_8
MYB ER NM_005375.2 v-myb myeloblastosis viral oncogene homolog (avian) 96 ER_8
XBP1 ER NM_005080.2 X-box binding protein 1 60 ER_8
BCL2 ER NM_000633.2 B-cell CLL/lymphoma 2 81 ER_4
GREB1 PGR NM_033090.1
NM_148903.1
NM_014668.2
GREB1 protein 77 PGR_5
PGR PGR NM_000926.3 progesterone receptor 118 PGR_5
ER_4
RAB31 PGR NM_006868.2 RAB31, member RAS oncogene family 109 PGR_5
RBBP8 PGR NM_203291.1
NM_203292.1
NM_002894.2
retinoblastoma binding protein 8 75 PGR_5
SERPINA3 PGR NM_001085.4 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 70 PGR_5
SCUBE2 PGR NM_020974.1 CEGP1, signal peptide, CUB domain, EGF-like 2 64 ER_4
ERBB2 HER2 NM_001005862.1
NM_004448.2
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog (avian)
120 HER2_2
GRB7 HER2 NM_005310.2 growth factor receptor-bound protein 7 70 HER2_2
CCNB2 Proliferation NM_004701.2 cyclin B2 73 PRO_10
CCNE2 Proliferation NM_057735.1
NM_057749.1
cyclin E2 70 PRO_10
CDC2 Proliferation NM_033379.2
NM_001786.2
cell division cycle 2, G1 to S and G2 to M 92 PRO_10
CENPF Proliferation NM_016343.3 centromere protein F, 350/400 ka (mitosin) 99 PRO_10
KIF20A Proliferation NM_005733.1 kinesin family member 20A 130 PRO_10
MKI67 Proliferation NM_002417.3 antigen identified by monoclonal antibody Ki-67 131 PRO_10
PRO_5
ORC6L Proliferation NM_014321.2 origin recognition complex, subunit 6 like (yeast) 78 PRO_10
PRC1 Proliferation NM_199413.1
NM_199414.1
NM_003981.2
protein regulator of cytokinesis 1 66 PRO_10
SPAG5 Proliferation NM_006461.3 sperm associated antigen 5 114 PRO_10
TOP2A Proliferation NM_001067.2 topoisomerase (DNA) II alpha 170 kDa 125 PRO_10
AURKA Proliferation NM_003600.2 STK15 aurora kinase A 85 PRO_5
BIRC5 Proliferation NM_001012271.1
NM_001168.2
baculoviral IAP repeat-containing 5 (survivin) 93 PRO_5
CCNB1 Proliferation NM_031966.2 cyclin B1 104 PRO_5
MYBL2 Proliferation NM_002466.2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 81 PRO_5
Abbreviation: AS, amplicon size
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(PRO_10) were defined as mean expression of all genes
in each category (Table 1). A RISK score comprising 25
genes was calculated as follows: RISK_25 = PRO_10
+HER2_2-(8 × ER_8+5 × PGR_5)/13. For comparison,
ER_4 and PRO_5 scores were calculated based on 4 and
5 genes described previously [27]. The genes corre-
sponding to ER_4 and PRO_5 scores corresponded to
the genes used for calculating the recurrence score (RS)
[29].
Concordance of molecular scores and pathological
parameters
Histopathological data of BIG 1-98 samples were
derived from a central review, with the exception of the
grade which was locally assessed. The ER and PgR status
were dichotomized into positive (≥ 10% immunoreactive
cells) or negative (<10%) [30]. Her2 was measured by
fluorescence in-situ hybridization or immunohistochem-
istry (IHC) and tumors were classified according to Ras-
mussen et al. [31]. The Ki-67 labeling index (LI) was
centrally assessed by IHC as described and classified
into low or high using the median LI (11%) as cut-off
[32]. The same assays and cut-offs were used for the 82
matched samples with the exception of Her2 which was
measured using the CB11 monoclonal antibody and
using a cut-off of ≥ 50% [33]. Continuous molecular
scores were compared to binary IHC parameters using
the area under the curve (AUC). The 95% confidence
intervals (CI) were estimated by a bootstrap method
(100 bootstraps). Two-sided Mann-Whitney tests were
used to assess the association between clinicopathologi-
cal factors and scores.
Statistical analyses
Primary endpoint of survival analyses was DFS as
defined previously [25]. Forty-five events were observed
in 342 patients with a median follow-up time (estimated
by reverse Kaplan-Meier [34]) of 60 months. DFS was
estimated by Kaplan Meier analysis. Patients were classi-
fied into low and high PRO or RISK scores using the
corresponding median score as cut-off. The differences
in survival experience between the two resulting groups
were assessed with log rank tests. Univariate and multi-
variate Cox proportional hazard models were used [35]
and hazard ratios (HR), CIs and p-values were obtained.
The multivariate models were assessed using the log-
likelihood and the deviance of residuals. Likelihood ratio
tests (LRT) were used to compare different nested mul-
tivariate models. No adjustments were made for multi-
ple testing. Univariate Cox proportional hazard models
were applied to estimate the rate of events and to pro-
duce corresponding plots.
Results
Reliable expression profiling from FFPE tumor tissue
Gene expression was measured from 34 genes using
TLDAs with RNA isolated from FF and FFPE material
of 82 breast cancers. These data were used solely for the
assessment of the expression profiling from FFPE mate-
rial. Pearson correlation coefficients between FF and
FFPE expression values for each tumor and all assays
ranged from 0.91 to 0.98. The mean increase of raw Ct
values derived of FFPE compared to matched FF tissues
was 1.30 units. This Ct shift was mostly compensated by
normalization (Additional File 2, Figure S1. and Addi-
tional File 3, Figure S2).
Unsupervised hierarchical clustering demonstrated the
stability of gene clusters and revealed an excellent agree-
ment between FF- and FFPE-based expression profiles
(Additional File 4, Figure S3). Molecular scores were
determined for ER, PGR, HER2 and PRO. A linear rela-
tionship of scores was found for RNA from FF and
RNA from FFPE material (Figure 1). Pearson correlation
coefficients for the four scores were 0.968, 0.974, 0.942
and 0.944, respectively. The distributions of ER_8,
PGR_5 and HER2_2 scores are shown as histograms
together with the fitted mixture of two Gaussian distri-
butions (Additional File 1, Figure S4) used for discrimi-
nating the subtypes.
The agreement between molecular scores and corre-
sponding binary IHC variables was assessed by receiver
operating characteristic (ROC) curves and AUC. AUCs
and 95% CI were calculated for ER_8 (FF = 0.940
(0.835-1.00), FFPE = 0.931 (0.804-1.00)), PGR_5 (FF =
0.919 (0.828-0.986), FFPE = 0.916 (0.806-0.987) and
HER2_2 (FF = 0.961 (0.895-1.00), FFPE = 0.963 (0.915-
0.993)). PRO_10 was compared with IHC data for Ki-67
using a cut-off of 11% and the resulting AUCs were
0.798 (0.609-0.900) for FF and 0.810 (0.660-0.907) for
FFPE, respectively. In conclusion, the agreement of the
IHC with FFPE samples was as good as with FF samples.
Concordance between pathological parameters and
molecular scores for tumors of the BIG 1-98 clinical trial
Molecular scoring was applied to an independent set of
tissue samples from Swiss patients participating in the
BIG 1-98 randomized clinical trial and scores were com-
pared to centrally assessed histopathological data by
ROC curves. From a total of 437 provided tumor sam-
ples 342 ER-positive tumors (78.3%) were suitable for
analysis. The AUC was 0.974 (95% CI = 0.946-0.995) for
HER2_2 and 0.847 (95% CI = 0.794-0.902) for PGR_5.
PRO_10 scores positively correlated with Ki-67 LI (Pear-
son correlation coefficient 0.51); the AUC was 0.815
(95% CI = 0.768-0.864) for Ki-67 binarized at 11% [32].
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The PRO_10 score correlates with histological grade and
other clinical factors
The histological grade was assessed according to Elston
and Ellis [36]. The PRO_10 score positively correlated
with Elston and Ellis scores and with grade (Pearson
correlation coefficient 0.453 and 0.409, respectively)
(Figure 2). Furthermore, PRO_10 scores were signifi-
cantly higher in Her2 positive tumors, in tumors larger
than 2 cm and in tumors with axillary lymph node
metastasis as compared to Her2 negative tumors, T1
tumors and N0 tumors (p ≤ 0.0015, Mann-Whitney
tests), respectively (data not shown).
PRO and RISK scores predict disease free survival in
lymph node positive patients and patients with grade II
breast cancer
The prognostic values of PRO_10 and RISK_25 scores
were assessed by their ability to assign patients to low
and high risk groups. Patients were stratified according
to histological grade and low or high PRO_10 and
RISK_25 scores using the corresponding medians as
cut-offs (Figure 3). As expected, patients with grade III
tumors had poorer DFS than patients with grade I or
grade II tumors (p = 0.0019, panel A). High PRO_10
scores correlated with poorer DFS compared to low
scores in all (p = 0.0043, panel B) and in histological
grade II tumors (p = 0.0024, panel C). Similarly,
RISK_25 discriminated between favorable and poor DFS
in all (p = 0.0005, panel D) and in node positive tumors
(p = 0.0009, panel E). Univariate Cox proportional
hazards regression analysis confirmed these
observations.
The PGR_5, PRO_10 and RISK_25 scores were all sig-
nificant predictors of DFS (p < 0.05) as were histological
grade, tumor size, number of positive lymph nodes and
Ki-67 LI (Table 2). The PRO_5 score was also a signifi-
cant predictor of DFS but PRO_10 score was numeri-
cally better than PRO_5 in terms of log-likelihood (L)
and deviance of residuals (D) (PRO_10: L = -223.35, D
= 225.83; PRO_5: L = -224.16, D = 227.57).
Figure 4 shows the estimated rate of recurrence as a
function of PRO_10, PGR_5 and RISK_25 scores. The
PRO_5, PRO_10 and the RISK_25 scores remained sig-
nificant predictors of DFS when applied to patients with
grade II breast cancer.
PRO_10 and PGR_5 scores are independent risk factors in
multivariate analyses
The impact of the molecular scores PRO_10 and PGR_5
was further documented in multivariate models
Figure 1 Comparison of scores computed from intact RNA and partially degraded RNA from FFPE material. Scores were determined for
RNA from FF material and RNA from corresponding FFPE tumor material of 82 patients. Scatter plots are shown between scores from FF and
FFPE tissues representing ER_8 (A), PGR_5 (B), HER2_2 (C) and PRO_10 (D) for each tumor. Pearson correlations are indicated.
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comprising clinicopathologic predictors and molecular
scores that were significant in univariate analyses.
Multivariate analyses revealed that PRO_10 is a pre-
dictor of DFS independent of tumor size (T), number of
positive lymph nodes (N), grade (G) and Ki-67 LI.
PRO_10 represents proliferation-related genes and it
was of interest to compare it to Ki-67. Table 2 shows
the results of multivariate analyses including T, N, G
and either Ki-67 (model 1) or PRO_10 (model 3) in
comparison with a model containing both markers
(model 2). The full model (model 2) was significantly
better than model 1 (LRT p = 0.0071). No significant
difference was found for PRO_10 between models 2 and
3 (LRT p = 0.8075). Thus, adding PRO_10 to T, N, G
and Ki-67 significantly improved the model. In contrast,
adding Ki-67 to T, N, G and PRO_10 did not bring
additional information.
The same procedure was used to evaluate whether
PGR_5 further improved model 6 containing T, N, G
and PRO_10 (Table 2). The full model including all 5
variables (model 5) performed better than model 4 (T,
N, G, PGR_5; LRT p = 0.0089) and model 6 (T, N, G,
PRO_10; LRT p = 0.0339). Both, PGR_5 and PRO_10
remained significant in model 5 suggesting that the two
scores contain independent information with respect to
prognosis and outcome.
Discussion
Gene expression profilings define clinically relevant gene
signatures [15,17,37,38]. For the present work, we
selected genes correlating with the ER, PgR, Her2 and
proliferative status using a meta-analysis of gene expres-
sion profiles [28]. The prognostic power of resulting
gene expression scores for ER, PgR, proliferation and
overall risk of recurrence was validated using tissues and
clinical data from a representative subset of participants
of trial BIG 1-98 confirming the correlation structure of
these genes and their association with clinical and out-
come variables.
Multiple genes representing each score were quanti-
fied by qRT-PCR. RNA from 82 matched FF and FFPE
tissues were compared by qRT-PCR on TLDAs. The
mean increase of raw Ct values between RNA from FF
and FFPE tissues was 1.3 units. This is similar to the
Figure 2 Comparison of scores and immunohistochemical analysis. Correlation of histological grading and PRO_10 score. The 342 tumors
were classified according to histological grading. The data are shown as boxplots with median (solid line), interquartile ranges (boxes) and
minimum and maximum non-outlier values (whiskers). The PRO_10 scores higher and lower than the median are indicated as red and blue dots,
respectively for each grade.
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findings of Cronin and co-workers (+2.0 units) in a
comparable setting [39]. Duration of formalin fixation,
storage time and conditions influence the quality of
RNA derived of FFPE tissues with direct effects on the
sensitivity of subsequent PCR reactions [40]. However,
normalization effectively compensated for this shift of
Ct values (Additional File 2, Fig S1 and Additional File
3, Figure S2).
The mean expression of eight genes related to ER and
five genes related to PgR were used to calculate the
ER_8 and PGR_5 scores. Scores representing different
functional categories were combined in RISK_25 score.
The molecular scores determined from 82 paired sam-
ples of FF and FFPE tumors were highly concordant, as
were molecular scores and immunohistochemically
assessed parameters demonstrating the reliability of the
procedure.
Molecular scores were validated in an independent set
of tumor tissues from 342 participants of trial BIG 1-98.
In contrast to histological analyses which can also be
performed from tissue sections that contain considerable
normal, stromal or fat components the architecture of
the tissue is completely lost during work up for molecu-
lar analyses and therefore, it was important to exclude
samples with inadequate tumor content. A histological
section was taken from the immediate vicinity of each
sample that was used for molecular analyses. Each sec-
tion was assessed by an experienced pathologist (H.J.A.)
and molecular analyses were restricted to samples con-
taining at least 30% tumor cells. For comparison, RNA
Figure 3 Survival data based on molecular scores. Kaplan-Meier plots for DFS. Patients were stratified into grade I (blue), II (green) and III (red
line) (A), into low (blue) and high (red) PRO_10 scores in all samples (B) and in Grade II samples (C). The RISK_25 score is shown for all samples
(D) and for tumors of patients with lymph node positive (N+) cancer (E). Median values of the scores were used as cut-offs. The p-values
correspond to Log-rank test.
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Table 2 Baseline characteristics.
Characteristic Patients with FFPE profiles from Swiss
participants used in the study (N = 342)
Provided material of
Swiss participants
(N = 437)
Patients of the BIG 1-98
population not used in the
study
(N = 7573)
Overall BIG 1-
98 population
(N = 8010)
Menopausal
category - N (%)
Postmen. before
chemo
321 (93.9) 413 (94.5) 7279 (96.1) 7692 (96.0)
Postmen. after
chemo
10 (2.9) 11 (2.5) 181 (2.4) 192 (2.4)
Premenopausal
(ineligible)
0 (0.0) 2 (0.5) 21 (0.3) 23 (0.3)
Uncertain status 10 (2.9) 10 (2.3) 92 (1.2) 102 (1.3)
Unknown/
missing
1 (0.3) 1 (0.2) 0 1 (<0.1)
Age at
randomization -
years
Median 62 62 61 61
Range 41-86 41-86 38-90 38-90
Tumor size - N
(%)
≤ 2 cm 195 (57.0) 251 (57.4) 4706 (62.1) 4957 (61.9)
> 2 cm 144 (42.1) 179 (41.0) 2794 (36.9) 2973 (37.1)
Unknown/
missing
3 (0.9) 7 (1.6) 73 (1.0) 80 (1.0)
Tumor grade - N
(%)
Grade 1 94 (27.5) 124 (28.4) 2007 (26.5) 2131 (26.6)
Grade 2 196 (57.3) 251 (57.4) 3649 (48.2) 3900 (38.7)
Grade 3 49 (14.3) 59 (13.5) 1166 (15.4) 1225 (15.3)
Unknown/
missing
3 (0.9) 3 (0.7) 751 (9.9) 754 (9.4)
Nodal status - N
(%)
Negative
(including Nx)
186 (54.4) 245 (56.1) 4342 (57.3) 4587 (57.3)
Positive 152 (44.4) 188 (43.0) 3123 (41.2) 3311 (41.3)
Unknown/
missing
4 (1.2) 4 (1.0) 108 (1.4) 112 (1.4)
ER and PgR
status - N (%)
ER pos and PgR
pos.
268 (78.4) 340 (77.8) 4715 (62.3) 5055 (63.1)
ER pos and PgR
neg.
66 (19.3) 87 (19.9) 1544 (20.4) 1631 (20.4)
ER pos and PgR
unknown
1 (0.3) 1 (0.2) 1153 (15.2) 1154 (14.4)
ER neg and PgR
pos.
5 (1.5) 7 (1.6) 136 (1.8) 143 (1.8)
ER unknown,
PGR pos.
0 0 7 (0.1) 7 (0.1)
Other 2 (0.6) 2 (0.5) 18 (0.3) 20 (0.2)
Local therapy -
N (%)
BCS and RT 236 (69.0) 310 (70.9) 3987 (52.7) 4297 (53.7)
BCS and no RT 13 (3.8) 16 (3.7) 228 (3.0) 244 (3.0)
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was also isolated from tumor-surrounding cells which
led to rather poor RNA recoveries from comparable tis-
sue areas (data not shown). However, this does not
exclude that tumor-surrounding cells may have a limited
impact on molecular scores in such analyses. Contami-
nation by non-tumor cells may be reduced by macrodis-
secting tumors before RNA isolation and molecular
assessment. The same procedure would also make
tumors accessible to molecular analysis when sections
contain less than 30% tumor cells.
Classification of patients by low and high PRO_10 and
RISK_25 scores corresponded to low and high risk of
recurrence. PRO, RISK and PGR scores were prognostic
for DFS not only in the entire patient population but
also in a subpopulation of patients with node positive
disease (Figure 3D and 3E). We provide evidence inde-
pendent of Genomic Health™ that a RISK score based
on similar biological processes as the recurrence score
(RS), but with other genes selected through a different
procedure, can predict DFS [29,41,42]. In contrast to the
RS which was validated with tamoxifen-treated patients,
PRO_10, RISK_25 and PGR_5 scores were validated
with patients treated with tamoxifen, letrozole or a
sequence of both drugs; therefore, they may apply to
patients who received either of these drugs.
Histological grading is an important factor in estimat-
ing the risk of recurrence of patients with breast cancer
[2,43]. Recently, Sortiriou and colleagues have developed
the gene expression grade index (GGI) based on the
expression of 97 genes related to proliferation. They
demonstrated that grade II cancers are comprised of
tumors which are similar to genomic grade I or grade
III with corresponding clinical outcomes [16,44]. Our
findings agree with these observations as grade II
tumors could be further classified into low and high risk
of recurrence by 10 genes (PRO_10) (Figure 3C) or even
by 5 genes (PRO_5 score) (data not shown). Seven of
the PRO_10 and three of the PRO_5 genes are also part
of GGI. The PRO_5 genes (Table 1) corresponded to
the proliferation-related genes of the RS [29]. The
assessment of gene signatures related to proliferation
such as GGI or PRO scores is of special interest in ER
positive, grade II breast cancer for whom therapeutic
decisions are often difficult. Both, GGI and RS were
shown to be associated with response to chemotherapy
[45,46]. In contrast to GGI which requires FF tumor
material, PRO scores or RS can be determined from a
few microtome slices or cores such as used for tissue
microarrays [47]. Material for molecular analysis can be
taken from the same FFPE tissue block used for histolo-
gical and immunohistochemical analyses without inter-
fering with clinicopathological workflow.
The prognostic value of Ki-67 in early breast cancer
was recently confirmed [48]. However, Ki-67 is not used
uniformly in clinical practice [49,50] as it appears to be
difficult to agree on cut-off values separating high and
low proliferation tumors or on its value in assisting the
choice of adjuvant therapy [50,51]. Therefore, instead of
dichotomizing Ki-67 it may be more feasible to use Ki-
67 as continuous variable [52]. Here, we made a com-
parison between centrally assessed Ki-67 LI and a qRT-
PCR based proliferation signature. The PRO_10 score
correlated with Ki-67 LI, and both were significant pre-
dictors of DFS in univariate Cox analyses. In multivari-
ate models however, PRO_10 offered superior
prognostic value and outperformed Ki-67 LI (Table 3).
Moreover, the PRO_10 score added independent prog-
nostic information to anatomical staging.
PgR, as measured by immunohistochemistry [30] or
microarray analysis [53], was shown to positively corre-
late with prognosis. Here we show that the molecular
PGR_5 score was also positively associated with DFS
(Figure 4) and added independent prognostic informa-
tion to anatomical staging and PRO_10 (Table 3). Thus,
PGR_5 and PRO_10 scores independently predict prog-
nosis in the BIG 1-98 population.
Compared to immunohistochemically assessed para-
meters, qRT-PCR based scores are quantitative,
Table 2: Baseline characteristics. (Continued)
Mastectomy and
RT
24 (7.0) 25 (5.7) 1415 (18.7) 1440 (18.0)
Mastectomy and
no RT.
68 (19.9) 85 (19.5) 1926 (25.4) 2011 (25.1)
Other 1 (0.3) 1 (0.2) 17 (0.2) 18 (0.2)
Adjuvant or
neoadjuvant
chemo (or both)
- N (%)
Yes 133 (38.9) 159 (36.4) 1865 (24.6) 2024 (25.3)
No 209 (61.1) 278 (63.6) 5708 (75.4) 5986 (74.7)
Abbreviations: BCS, breast conserving surgery; Nx, nodal status unknown; postmen., postmenopausal; RT, radiotherapy; PgR, progesterone receptor; pos., positive;
neg., negative
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relatively independent on operator expertise and less
affected by inter-observer variability. The procedure is
simple, economical and can be standardized easily with
good control genes, reference samples and quality con-
trol procedures.
The results of this study are based on a limited num-
ber of patients and follow-up time (60 months). Similar
Figure 4 Expected rate of disease-free survival (DFS) . The
expected rate of events at 60 months (solid line) is shown as a
function of PRO_10 (A), PGR_5 (B) and RISK_25 scores (C). The 95%
confidence intervals are indicated (dashed lines). Vertical lines
represent the median of all scores (solid line) and 25% and 75%
quantiles (dashed lines).
Table 3 Cox Proportional Hazard Analyses.
Covariate P-value HR (95% CI)
Univariate Analyses*
Clinicopathological Variables
HER2 0.7816 1.18 (0.36 - 3.84)
PgR 0.5147 0.78 (0.36 - 1.66)
Histological grade 0.0032 1.99 (1.26 - 3.14)
Ki-67 LI 0.0226 1.02 (1.00 - 1.04)
Tumor size 0.0047 1.22 (1.06 - 1.39)
Number of positive nodes <0.0001 1.13 (1.08 - 1.18)
Treatment (4 categories) 0.1540 -
Molecular scores
HER2_2 0.1080 1.20 (0.96 - 1.51)
PGR_5 0.0344 0.66 (0.44 - 0.97)
PRO_5 0.0003 2.14 (1.42 - 3.22)
PRO_10 <0.0001 2.09 (1.45 - 3.00)
RISK_25 0.0001 1.54 (1.24 - 1.91)
Multivariate Analyses: Comparison of PRO_10 and Ki-67 LI**
Model 1: log-likelihood = -179.38, Deviance = 188.11
Number of positive nodes <0.0001 1.19 (1.12 - 1.27)
Tumor size 0.0370 1.19 (1.01 - 1.39)
Grade 0.4200 1.25 (0.72 - 2.17)
Ki-67 LI 0.1300 1.02 (1.00 - 1.04)
Model 2: log-likelihood = -175.75, Deviance = 180.71
Number of positive nodes <0.0001 1.19 (1.12 - 1.27)
Tumor size 0.1300 1.14 (0.96 - 1.34)
Grade 0.9600 0.99 (0.55 - 1.76)
PRO_10 0.0092 2.12 (1.20 - 3.72)
Ki-67 LI 0.8100 1.00 (0.97 - 1.03)
Model 3: log-likelihood = -175.78, Deviance = 180.77
Number of positive nodes <0.0001 1.19 (1.12 - 1.27)
Tumor size 0.1200 1.14 (0.97 - 1.34)
Grade 0.9400 0.98 (0.55 - 1.74)
PRO_10 0.0026 2.03 (1.28 - 3.23)
Multivariate Analyses: Role of PGR_5***
Model 4: log-likelihood = -215.27, Deviance = 214.30
Number of positive nodes <0.0001 1.12 (1.07 - 1.16)
Tumor size 0.2000 1.11 (0.95 - 1.30)
Grade 0.0170 1.78 (1.11 - 2.87)
PGR_5 0.0570 0.68 (0.45 - 1.01)
Model 5: log-likelihood = -211.85, Deviance = 208.03
Number of positive nodes <0.0001 1.06 (1.06 - 1.16)
Tumor size 0.4300 1.07 (0.91 - 1.26)
Grade 0.3000 1.32 (0.78 - 2.23)
PRO_10 0.0092 1.73 (1.15 - 2.62)
PGR_5 0.0360 0.65 (0.43 - 0.97)
Model 6: log-likelihood = -214.10, Deviance = 211.25
Number of positive nodes <0.0001 1.11 (1.06 - 1.16)
Tumor size 0.1700 1.13 (0.95 - 1.34)
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analyses with independent, larger sample sizes and more
mature follow-up data are planned to further consoli-
date the prognostic and possibly predictive value of the
proposed scores in each treatment arm separately.
Gene expression profiling has improved the under-
standing of molecular subtypes of breast cancer. FFPE
material is not widely used although it may facilitate
and speed up the development and validation of novel
gene signatures due to the availability of well-character-
ized tissues from numerous clinical trials [54,55]. The
same material can be used for molecular diagnostics.
The investigation of gene signatures may become more
important in the future as an increasing proportion of
agents under development for breast cancer treatment
have defined molecular targets. Early integration of bio-
marker analysis in the drug development process has
the potential to improve the specificity and efficiency of
novel therapeutics. This opens the possibility to further
individualize therapy of patients with breast cancer.
Conclusions
We define four molecular scores based on quantitative
measurement of gene expression with RNA derived of
FFPE tissues. The genes for each score were selected
from a large meta-analysis of microarrays. The genes do
not coincide with genes used for other molecular scores
like the RS (except genes that were previously used as
immunohistochemical markers such as ER, PgR or
Her2). Two of the described scores are shown to be
independent predictors of disease-free survival of post-
menopausal patients with operable, estrogen receptor
positive breast cancer. The proliferation-associated score
outperforms the Ki-67 labeling index measured by
immunohistochemistry.
List of abbreviations
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